Girao Tiago 4

What Happened

• Tiago Girao, CFO of Immunovant (IMVT), exercised options to acquire 10,000 common shares at $15.90 per share (total cost $159,000) and then sold 10,000 shares in the open market for a weighted average price of $38.46 per share (total proceeds ~$384,600) on June 26, 2026. The filing also reports a related derivative disposition of 10,000 shares at $0.00 (see Key Details).

Key Details

• Transaction date: 2026-06-26.
• Exercise: 10,000 shares @ $15.90 = $159,000 (code M).
• Sale: 10,000 shares @ weighted avg $38.46 = $384,600 (code S); sale prices ranged from $38.00 to $38.90 per share (footnote F1).
• Derivative disposition: 10,000 shares reported disposed @ $0.00 (code M) — noted in the filing alongside the exercise/sale.
• Shares owned after transaction: not specified in the provided filing extract.
• Timeliness: Filing date matches the report date (timely filed).
• Footnote on award (F2): options were granted May 1, 2025; 25% vested April 21, 2026, with remaining vesting quarterly over three years, subject to continued service.

Context

• This sequence (exercise followed by an immediate sale) is commonly a cashless or partial cashless exercise and sale to cover the exercise cost and/or tax obligations; the filing shows exercise and sale on the same day. The weighted-average sale price and the option vesting footnote indicate the shares derived from an option award granted in 2025. No indication in the filing of a 10b5‑1 plan or a late filing.